Trial Profile
A Real World Pharmacodynamic Study Assessing Platelet Inhibition During Treatment with Cangrelor and Transition Phase with Oral P2Y12-Receptor Inhibitors in Patients with Acute Coronary Syndromes (ACS).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Oct 2017
Price :
$35
*
At a glance
- Drugs Cangrelor (Primary) ; Prasugrel; Ticagrelor
- Indications Coronary thrombosis
- Focus Pharmacodynamics
- 28 Oct 2017 New trial record